Several evidence outcomes have shown that DYRK1A is involved in the progression of T2DM, and, therefore, inhibitors of this kinase could be important therapeutic agents for its treatment by promoting β-cell proliferation [117]. The gene discussed is DYRK1A; the disease is type 2 diabetes mellitus.